A Study of Subcutaneously Administered Herceptin (Trastuzumab) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer
Information source: Hoffmann-La Roche
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Breast Cancer
Intervention: Trastuzumab - intravenous solution (Drug); Trastuzumab - subcutaneous solution (Drug); Chemotherapy (Drug)
Phase: Phase 2
Status: Terminated
Sponsored by: Hoffmann-La Roche Official(s) and/or principal investigator(s): Clinical Trials, Study Director, Affiliation: Hoffmann-La Roche
Summary
This open-label, randomized crossover study evaluated the quality of life, efficacy, and
safety of subcutaneous Herceptin (trastuzumab) injected either into the thigh or the upper
arm of participants with early HER2-positive breast cancer.
Clinical Details
Official title: LISAH: An Open-label, Randomised Phase II Study Assessing Quality of Life Associated With Subcutaneous Trastuzumab Injected Into the Thigh or Upper Arm in Patients With HER2-positive Early Breast Cancer
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Quality of Life Score
Secondary outcome: Overall SurvivalDisease-free Survival Health Care Provider's Satisfaction With the Injection Site Participant's Satisfaction With the Injection Site Percentage of Participants Preferring Each Injection Site
Detailed description:
In the run-in phase, participants received trastuzumab intravenously every 3 weeks for 18
weeks (Cycles 1-6). They first received trastuzumab 8 mg/kg once (Cycle 1) followed by
trastuzumab 6 mg/kg 5 times for 15 weeks (Cycles 2-6). Participants could also receive a
maximum of 6 cycles of standard chemotherapy for early breast cancer (neo-adjuvant or
adjuvant) in the run-in phase.
Following the run-in phase, participants were randomized to receive trastuzumab 600 mg
subcutaneously every 3 weeks in the thigh and upper arm in a cross-over design for a total
of 24 weeks (Cycles 7-14). They received trastuzumab either in the thigh first for 4 cycles
(Cycles 7-10) followed by trastuzumab in the upper arm for 4 cycles (Cycles 11-14) or the
upper arm first (Cycles 7-10) followed by the thigh (Cycles 11-14). For Cycles 15-18,
participants could choose the injection site for trastuzumab 600 mg subcutaneously every 3
weeks.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Female and male patients ≥ years of age.
- HER2-positive early breast cancer.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- Hormonal therapy will be allowed as per institutional guidelines.
- Patients must be Herceptin (trastuzumab) naïve.
- Left ventricular ejection fraction (LVEF) of ≥ 55%.
- Histologically confirmed non-metastatic primary invasive adenocarcinoma of the
breast.
- No evidence of residual, locally recurrent, or metastatic disease after completion of
surgery and chemotherapy, or during concurrent chemotherapy (neo-adjuvant or
adjuvant).
- Use of concurrent curative radiotherapy will be permitted.
Exclusion Criteria:
- History of other malignancy which could affect compliance with the protocol or
interpretation of results. Patients with curatively treated carcinoma in situ of the
cervix or basal cell carcinoma, and patients with other curatively treated
malignancies who have been disease-free for at least 5 years, are eligible.
- Patients with severe dyspnea at rest or requiring supplementary oxygen therapy.
- Patients with other concurrent serious diseases that may interfere with planned
treatment, including severe pulmonary conditions/illness.
- Serious cardiac illness or medical conditions that would preclude the use of
Herceptin, specifically, a history of documented congestive heart failure (CHF),
high-risk uncontrolled arrhythmias, angina pectoris requiring medication, clinically
significant valvular disease, evidence of transmural infarction on electrocardiogram
(ECG), or diagnosed poorly controlled hypertension.
- Pregnant or lactating women.
- Women of childbearing potential and male patients with partners of childbearing
potential who are unable or unwilling to use adequate contraceptive measures during
study treatment.
- Concurrent enrollment in another clinical trial using an investigational anti-cancer
treatment, including hormonal therapy, bisphosphonate therapy, and immunotherapy,
within 28 days prior to the first dose of study treatment.
- Known hypersensitivity to trastuzumab, murine proteins, to any of the excipients of
Herceptin including hyaluronidase, or a history of severe allergic or immunological
reactions, eg, difficult to control asthma.
- Inadequate bone marrow, hepatic, or renal function.
Locations and Contacts
Innsbruck 6020, Austria
Salzburg 5020, Austria
Additional Information
Starting date: September 2013
Last updated: September 25, 2014
|